Stock Price

Acurx Pharmaceuticals preps for pivotal Phase 3 trials for its novel C. diff antibiotic, Ibezapolstat, with global regulatory alignment in place.

Indian clean energy giant ReNew posts stellar results, slashing losses and boosting profits, thanks to its booming solar manufacturing division.

Nicox's novel glaucoma drug NCX 470 receives positive FDA feedback, keeping its 2026 U.S. market submission on track to challenge a $7B industry.

The veteran-founded coffee brand is on the clock after its stock price fell below $1.00, triggering a six-month window to brew a market turnaround.

Safe Bulkers sells a 14-year-old ship for $35.2M, capitalizing on a strong market to fund a new generation of eco-friendly vessels.

Enpro's 3.2% dividend hike reflects more than just stability; it's a sign of a successful growth strategy and robust health in key tech sectors.

Influential proxy advisors ISS and Glass Lewis urge shareholders to approve the C$36.60 per share cash offer, framing it as a secure exit for investors.

With $100M from its new IPO, XFLH Capital joins a resurgent SPAC market. But can its Asia-focused strategy overcome a history of investor risk?

Top policymakers, including Dr. Agustín Carstens and FATF President Luis Urrutia Corral, will convene in Mérida to address critical cross-border tax issues.

U Power (UCAR) presents its AI-driven energy grid strategy at a key conference, betting on a tech pivot to reignite investor interest after a steep decline.

Rising repair costs and market volatility are forcing homeowners to rethink their selling strategy, seeking certainty over a potential bidding war.

LP's 7% dividend hike reflects strong financials and a cautiously optimistic outlook for the evolving construction and housing markets in 2026.

With triple-digit loan volume growth and a landmark AAA rating, Figure Technology Solutions' latest results suggest tokenized assets are finally breaking through.

The esports betting firm has paused all player activity and announced massive layoffs, signaling a potential sale amid a deepening financial crisis.

With a $15 million funding boost, Nasus Pharma is accelerating its powder-based intranasal epinephrine, NS002, challenging the EpiPen's dominance.

Iterum Therapeutics secures key Medicare access for its antibiotic ORLYNVAH™, but a costly FDA trial requirement for a new use casts a shadow on its future.

A new software upgrade uses AI to make low-cost drones perform like high-end systems, a breakthrough with major implications for defense and industry.

Chinese data center giant VNET promotes Peter Zhang to SVP, signaling a focus on stability and governance as it navigates rapid AI-driven growth.

The Canadian restaurant giant defied a tough market in 2025, posting record sales and boosting investor payouts through strategic promotions and delivery.

The uranium giant posted a massive jump in 2025 earnings, fueled by strategic investments and a global rush for clean, secure energy. Here's what's next.